Chang Jee Suk, Song Seung Yong, Oh Joo Hyun, Lew Dae Hyun, Roh Tai Suk, Kim Se Young, Keum Ki Chang, Lee Dong Won, Kim Yong Bae
Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Department of Plastic and Reconstructive Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Front Oncol. 2019 Apr 9;9:243. doi: 10.3389/fonc.2019.00243. eCollection 2019.
This study investigated the association between radiation dose and complication rate in patients who underwent breast reconstruction to understand the role of radiation hypofractionated regimen, boost radiation therapy (RT), and RT techniques. We retrospectively evaluated 75 patients treated with post-mastectomy adjuvant RT for breast cancer in the setting of two-stage prosthetic breast reconstruction. Near maximum radiation dose (D) in the 2 or 0.03 cc of reconstructed breast or overlying breast skin was obtained from dose-volume histograms. Post-RT complications occurred in 22.7% of patients. Receiver operating characteristic analysis showed that all near D parameters were able to predict complication risk, which retained statistical significance after adjusting other variables (odds ratio 1.12 per Gy, 95% confidence interval 1.02-1.23) with positive dose-response relationship. In multiple linear regression model ( = 0.92), conventional fractionation (β = 11.7) and 16 fractions in 2.66 Gy regimen (β = 3.9) were the major determinants of near D compared with 15 fractions in 2.66 Gy regimen, followed by utilization of boost RT (β = 3.2). The effect of bolus and dose inhomogeneity seemed minor ( > 0.05). The location of hot spot was not close to the high density metal area of the expander, but close to the surrounding areas of partially deflated expander bag. This study is the first to demonstrate a dose-response relationship between risk of complications and near D, where hypofractionated regimen or boost RT can play an important role. Rigorous RT-quality assurance program and modification of dose constraints could be considered as a critically important component for ongoing trials of hypofractionation. Based on our findings, we initiated a multi-center retrospective study (KROG 18-04) and a prospective study (NCT03523078) to validate our findings.
本研究调查了接受乳房重建的患者中辐射剂量与并发症发生率之间的关联,以了解低分割放疗方案、追加放疗(RT)和放疗技术的作用。我们回顾性评估了75例在两阶段假体乳房重建背景下接受乳腺癌乳房切除术后辅助放疗的患者。从剂量体积直方图中获取重建乳房或覆盖乳房皮肤2 cc或0.03 cc内的接近最大辐射剂量(D)。放疗后并发症发生在22.7%的患者中。受试者工作特征分析表明,所有接近D的参数都能够预测并发症风险,在调整其他变量后仍具有统计学意义(每Gy的优势比为1.12,95%置信区间为1.02 - 1.23),呈正剂量反应关系。在多元线性回归模型(R² = 0.92)中,与2.66 Gy方案的15次分割相比,常规分割(β = 11.7)和2.66 Gy方案的16次分割(β = 3.9)是接近D的主要决定因素,其次是追加放疗的使用(β = 3.2)。推注和剂量不均匀性的影响似乎较小(P > 0.05)。热点位置不靠近扩张器的高密度金属区域,而是靠近部分瘪缩的扩张器袋的周边区域。本研究首次证明了并发症风险与接近D之间的剂量反应关系,其中低分割放疗方案或追加放疗可发挥重要作用。严格的放疗质量保证计划和剂量限制的修改可被视为正在进行的低分割放疗试验的关键重要组成部分。基于我们的发现,我们启动了一项多中心回顾性研究(KROG 18 - 04)和一项前瞻性研究(NCT03523078)以验证我们的发现。